Condition (MeSH)
Hyperlipoproteinemia Type I
ClinicalTrials.gov lists 34 trials for Hyperlipoproteinemia Type I or a narrower condition beneath it. Ionis Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
34 of the 34 trials are tagged with Hyperlipoproteinemia Type I itself; the rest are tagged with a narrower condition beneath it.
When did Hyperlipoproteinemia Type I trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperlipoproteinemia Type I trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 10 |
| Not applicable | 1 |
| Observational | 8 |
| Expanded access | 3 |
How many Hyperlipoproteinemia Type I trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Available | 1 |
| Completed | 17 |
| Approved for marketing | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperlipoproteinemia Type I trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ionis Pharmaceuticals, Inc. | 6 |
| Amsterdam Molecular Therapeutics | 4 |
| Akcea Therapeutics | 3 |
| Arrowhead Pharmaceuticals | 3 |
| Novartis Pharmaceuticals | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Hyperlipoproteinemia Type I? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Olezarsen | 5 |
| Volanesorsen | 3 |
| Plozasiran | 3 |
| (LMW)heparin | 2 |
| alipogene tiparvovec | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LCQ908 | 3 |
| Mofetil Mycophenolate | 3 |
| Orlistat 60 | 2 |
| Cyclosporine 0.05% | 2 |
| CS-121 | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperlipoproteinemia Type I trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pancreatitis acute | 13 | 5 |
| PANCREATITIS | 9 | 2 |
| Pancreatitis | 9 | 3 |
| PANCREATITIS ACUTE | 7 | 2 |
| Thrombocytopenia | 6 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hyperlipoproteinemia Type I? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. | The New England journal of medicine | 2025 | Yes |
| Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. | The New England journal of medicine | 2024 | Yes |
| Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. | Nature medicine | 2023 | Yes |
| 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes. | The Journal of clinical endocrinology and metabolism | 2021 | Yes |
| Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. | The lancet. Diabetes & endocrinology | 2021 | Yes |
Showing 5 of 28 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Familial lipoprotein lipase deficiency | Point prevalence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Familial lipoprotein lipase deficiency | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.